Regorafenib News and Research

RSS
Onyx announces results from regorafenib Phase 3 trial on GIST

Onyx announces results from regorafenib Phase 3 trial on GIST

Mayo Clinic experts available to discuss latest colorectal cancer research and treatment

Mayo Clinic experts available to discuss latest colorectal cancer research and treatment

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Experimental drug helps patients with advanced colon cancer

Experimental drug helps patients with advanced colon cancer

New research into treatment, prognosis and early detection of GI cancers

New research into treatment, prognosis and early detection of GI cancers

Regorafenib lengthens lives of patients with metastatic colorectal cancer

Regorafenib lengthens lives of patients with metastatic colorectal cancer

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

Bayer's regorafenib Phase 3 trial on metastatic colorectal cancer meets primary endpoint

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.